Porto Scientists Slow Aging in Progeria Mice by Switching On a DNA-Repair Protein

A drug-like molecule that switches on a little-known DNA-repair protein slowed the signs of aging and extended both healthspan and lifespan in mice with a premature-aging disease, according to a study published on November 1, 2026 in Nature Communications. The work, led by Elsa Logarinho and Joana C. Macedo at the i3S research institute of the University of Porto in Portugal, with co-authors including longevity researchers Vera Gorbunova and Andrei Seluanov of the University of Rochester, adds a new candidate to the short list of compounds that target one of aging’s core drivers: damaged DNA.

The finding is early and comes from a disease model rather than ordinary aging. But it lands at a moment when investors are pouring billions into longevity science and are increasingly asking which mechanisms can actually be turned into medicines.

What the Researchers Found

The study centers on KIF2C, a member of the kinesin-13 family of proteins that the team had previously found to be switched down in aged cells. KIF2C is best known for its role in cell division, but it also helps repair double-strand breaks, the most dangerous kind of DNA damage because both strands of the helix are severed at once.

According to the paper’s abstract, the researchers used a small-molecule agonist, a compound that boosts KIF2C’s activity, and tested it in two genetic conditions marked by heavy DNA damage and accelerated aging: Hutchinson-Gilford progeria syndrome and Down syndrome. In aged cells and in cells derived from patients with either condition, the compound improved the repair of double-strand breaks.

The team traced the effect to the membrane that surrounds the cell’s nucleus. The compound restored the formation of inward folds in that nuclear envelope, which are driven by microtubules in the surrounding cytoplasm and which the authors link to more effective repair of broken DNA. Better repair was accompanied by improvements in nuclear structure and in patterns of gene activity in the patient-derived cells.

The headline result came from animals. When the KIF2C agonist was injected under the skin of mice with progeria, it eased aging-related features and extended both healthspan, the period of life spent in good health, and lifespan, the authors report.

The Caveats Matter

As the science summary site AgingResearch.News points out, the abstract does not state how much lifespan increased or how many mice were studied. The lifespan data also come from a mouse model of progeria, a rare and severe disease, not from naturally aging animals or from people. Progeria models are useful because they compress aging into a short window, but results in them do not always carry over to normal aging.

The paper also carries a disclosure worth noting. Its competing-interests statement says Logarinho is an inventor on an active patent covering the use of a compound called UMK57 to enhance the activity of MCAK, another name for the kinesin-13 protein KIF2C, in elderly cells. That points to a possible commercial path for this line of research, and readers should weigh the results with that interest in mind.

Who Paid for It

The funding list reads like a map of today’s longevity ecosystem. According to the paper, support came from the Progeria Research Foundation, the Fondation Jérôme Lejeune, which focuses on Down syndrome, Portugal’s Foundation for Science and Technology, a European Research Council Synergy Grant, and the Maximon Longevity Prize 2022, from Switzerland-based Maximon AG. That mix of patient-advocacy money, public research grants and private longevity capital is increasingly typical of how early aging science gets financed.

Why It Matters for Business

Rare diseases are the on-ramp for longevity drugs. Regulators do not recognize aging itself as a disease, so companies developing anti-aging therapies typically seek approval for a specific condition first. Progeria and Down syndrome, both marked by accelerated aging, offer exactly that kind of defined target. A compound that shows benefit in those conditions can build a safety and efficacy record before anyone tries to test it in broader aging populations.

Investors want mechanisms they can measure. A recent L.E.K. Consulting analysis estimates that longevity-focused companies raised about US$8.5 billion across roughly 331 deals in 2024 and about US$5.7 billion across around 170 deals in 2025, with capital concentrating in fewer, better-funded companies. The firm says clinical readouts through 2027 and 2028 will show which mechanisms deserve further investment. DNA repair is a well-established hallmark of aging, and a molecule that measurably improves it gives developers a clearer biological story than many earlier anti-aging bets.

Big rounds are going to platforms closer to the clinic. According to New Market Pitch, NewLimit’s US$435 million Series C alone accounted for more than half of disclosed longevity biotech funding in its latest 12-month tally, while the US$20 million to US$50 million middle of the market has thinned. For an academic program like Porto’s, that means the gap between a strong mouse result and a fundable company remains wide, and the next steps, such as data in normally aging animals and early safety work, will decide whether it attracts serious capital.

The healthspan market is the real prize. Employers, insurers and health systems all carry the cost of age-related decline. Therapies that keep people healthier for longer, rather than simply adding years, are where most of the economic value sits, which is why studies that report healthspan alongside lifespan draw attention. Que.com recently covered another mouse study in this vein, in which blocking one aging enzyme extended mouse lifespan by 17%.

The Bottom Line

The Porto team has shown that switching on KIF2C can improve DNA repair in aged and patient cells and extend health and life in progeria mice. That is a meaningful proof of concept for treating genome instability as a drug target. It is not yet evidence that the approach will slow normal aging in people. The next milestones to watch are the size of the lifespan effect in the full paper, results in naturally aging animals, and whether the patented compound family moves toward a company or a clinical program.

Edited by Coron @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous